Summary

This article discusses the initial 52-week data from the COMET trial which showed that etanercept in combination with methotrexate (MTX) was superior to MTX alone in providing clinical remission, radiographic non-progression, and normalized function.

  • rheumatoid arthritis clinical trials
View Full Text